Correlation of MicroRNA Expression Profile with Clinical Response to Tumor Necrosis Factor Inhibitor in Treating Rheumatoid Arthritis Patients: A Prospective Cohort Study

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2019 Jun 28

PMID 31245894

Citations 22

Authors

Yaqiong Liu

Yonghong Han

Huanru Qu

Jingpin Fang

Mei Ye

Wanling Yin

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to explore the correlation of circulating microRNA (miRNA) expression profile with clinical response to tumor necrosis factor (TNF) inhibitor in treating rheumatoid arthritis (RA) patients.

Methods: Baseline PBMC samples from eight responders and eight non-responders after 24-week TNF inhibitor (etanercept) treatment were subjected to miRNA microarray. Then, top 10 dysregulated miRNAs were selected and further validated by quantitative polymerase chain reaction (qPCR) in baseline PBMC samples from 92 RA patients treated with 24-week TNF inhibitor (etanercept). Responders and non-responders were divided referring to the decline in disease activity score in 28 joints.

Results: In microarray assay, total 59 upregulated and 78 downregulated miRNAs were identified in responders compared to non-responders, which were mainly enriched in regulating immune- and inflammation-related biological processes and pathways. The top 10 dysregulated miRNAs were as follows: miR-192-5p, miR-146a-5p, miR-19b-3p, miR-320c, miR-335-5p, miR-149-3p, miR-766-3p, let-7a-5p, miR-24-3p, and miR-1226-5p. In qPCR validation, miR-146a-5p was increased, while let-7a-5p was decreased in responders compared with non-responders. Multivariate logistic analysis illuminated that miR-146a-5p and CRP independently correlated with higher clinical response, while let-7a-5p and biologics history independently associated with lower clinical response. Subsequently, receiver operating characteristic curve showed that combination of these four independent factors presented with a great predictive value for clinical response with area under curve: 0.863, 95% CI 0.781-0.945.

Conclusion: miRNA expression profile is closely implicated in the treatment efficacy of TNF inhibitor, and combined measurement of miR-146a-5p, let-7a-5p, CRP, and biologics history disclosed a great predictive value for clinical response to TNF inhibitor in RA patients.

Citing Articles

MicroRNA profiling of low concentration extracellular vesicle RNA utilizing NanoString nCounter technology.

Crossland R, Albiero A, Sanjurjo-Rodriguez C, Reis M, Resteu A, Anderson A J Extracell Biol. 2024; 2(1):e72.

PMID: 38938446 PMC: 11080777. DOI: 10.1002/jex2.72.

Towards Personalized Medicine in Rheumatoid Arthritis.

Sharma S, Bluett J Open Access Rheumatol. 2024; 16:89-114.

PMID: 38779469 PMC: 11110814. DOI: 10.2147/OARRR.S372610.

Overexpression of Synoviolin and miR-125a-5p, miR-19b-3p in peripheral blood of rheumatoid arthritis patients after treatment with conventional DMARDs and methylprednisolone.

Karamali N, Mahmoudi Z, Roghani S, Assar S, Pournazari M, Soufivand P Clin Rheumatol. 2023; 43(1):147-157.

PMID: 38049563 DOI: 10.1007/s10067-023-06808-0.

Differential Expression Profiles of Plasma Exosomal microRNAs in Rheumatoid Arthritis.

Yang X, Wang Z, Zhang M, Shuai Z J Inflamm Res. 2023; 16:3687-3698.

PMID: 37663759 PMC: 10473432. DOI: 10.2147/JIR.S413994.

Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis.

Jiang Y, Zhong S, He S, Weng J, Liu L, Ye Y Front Immunol. 2023; 14:1087925.

PMID: 36817438 PMC: 9929281. DOI: 10.3389/fimmu.2023.1087925.

References

Roush S, Slack F . The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505-16. DOI: 10.1016/j.tcb.2008.07.007. View

Castro-Villegas C, Perez-Sanchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limon P . Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther. 2015; 17:49. PMC: 4377058. DOI: 10.1186/s13075-015-0555-z. View

Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X . MicroRNA: function, detection, and bioanalysis. Chem Rev. 2013; 113(8):6207-33. DOI: 10.1021/cr300362f. View

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

Aletaha D, Smolen J . Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018; 320(13):1360-1372. DOI: 10.1001/jama.2018.13103. View

Pauley K, Satoh M, Chan A, Bubb M, Reeves W, Chan E . Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008; 10(4):R101. PMC: 2575615. DOI: 10.1186/ar2493. View

Bordon Y . Autoimmunity: MicroRNA-23b keeps TABs on tissue inflammation. Nat Rev Immunol. 2012; 12(7):474. DOI: 10.1038/nri3250. View

Hermann H, Runnel T, Aab A, Baurecht H, Rodriguez E, Magilnick N . miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in Psoriasis. J Invest Dermatol. 2017; 137(9):1945-1954. PMC: 5977389. DOI: 10.1016/j.jid.2017.05.012. View

Legesse-Miller A, Elemento O, Pfau S, Forman J, Tavazoie S, Coller H . let-7 Overexpression leads to an increased fraction of cells in G2/M, direct down-regulation of Cdc34, and stabilization of Wee1 kinase in primary fibroblasts. J Biol Chem. 2009; 284(11):6605-9. PMC: 2652271. DOI: 10.1074/jbc.C900002200. View

10.

Feng Z, Li J, Ren J, Lv Z . [Expression of miR-146a and miR-16 in peripheral blood mononuclear cells of patients with rheumatoid arthritis and their correlation to the disease activity]. Nan Fang Yi Ke Da Xue Xue Bao. 2011; 31(2):320-3. View

11.

Fan Y, Ding S, Sun Y, Zhao B, Pan Y, Wan J . MiR-377 Regulates Inflammation and Angiogenesis in Rats After Cerebral Ischemic Injury. J Cell Biochem. 2017; 119(1):327-337. DOI: 10.1002/jcb.26181. View

12.

Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M . The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum. 2011; 63(6):1582-90. DOI: 10.1002/art.30321. View

13.

Xiao G, Wang X, Yu Y . CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2. Cell Physiol Biochem. 2017; 43(2):840-851. DOI: 10.1159/000481610. View

14.

Burmester G, Pope J . Novel treatment strategies in rheumatoid arthritis. Lancet. 2017; 389(10086):2338-2348. DOI: 10.1016/S0140-6736(17)31491-5. View

15.

Brennan E, Wang B, McClelland A, Mohan M, Marai M, Beuscart O . Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis. Diabetes. 2017; 66(8):2266-2277. DOI: 10.2337/db16-1405. View

16.

Huang W, Li Z, Zhao L, Zhao W . Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. Biomed Pharmacother. 2017; 92:46-57. DOI: 10.1016/j.biopha.2017.05.060. View

17.

Xu K, Xu P, Yao J, Zhang Y, Hou W, Lu S . Reduced apoptosis correlates with enhanced autophagy in synovial tissues of rheumatoid arthritis. Inflamm Res. 2012; 62(2):229-37. DOI: 10.1007/s00011-012-0572-1. View

18.

van Gestel A, Prevoo M, van t Hof M, van Rijswijk M, van de Putte L, van Riel P . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against.... Arthritis Rheum. 1996; 39(1):34-40. DOI: 10.1002/art.1780390105. View

19.

Poole E, Lee I, Ridker P, Buring J, Hankinson S, Tworoger S . A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer. Am J Epidemiol. 2013; 178(8):1256-64. PMC: 3792725. DOI: 10.1093/aje/kwt098. View

20.

McInnes I, Schett G . Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017; 389(10086):2328-2337. DOI: 10.1016/S0140-6736(17)31472-1. View